Clinical Trials
11 trialsNCT06239272 2026-05-19
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT02180867 2026-05-04
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT05100134 2026-04-01
Managed Access Programs for LDK378, Ceritinib
Novartis
No longer available
NCT05160922 2026-03-30
Crizotinib Continuation Clinical Study
Pfizer
Phase 4 Active not recruiting
NCT04925609 2025-12-05
Briga-PED
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
NCT04094610 2025-11-19
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT01524926 2023-12-11
CREATE
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT01742286 2020-06-09
Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
Novartis
Phase 1 Completed
NCT02465528 2019-12-27
Ceritinib Rare Indications Study in ALK+ Tumors
Novartis
Phase 2 Terminated
NCT03874273 2019-03-14
Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 2/3 Unknown
NCT03085186 2017-08-29
Treatment With Crizotinib Single Patient Expanded Access IND 134375
University of Pittsburgh
No longer available